AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations

By /

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.

Scroll to Top